at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
![Kura Oncology logo](/files/LOGO/1422143-KURA.png)
Company profile
Ticker
KURA
Exchange
Website
CEO
Troy Wilson
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ZETA ACQUISITION CORP III
SEC CIK
KURA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Jun 24
8-K
Departure of Directors or Certain Officers
7 Jun 24
8-K
Other Events
24 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Kura Oncology Reports First Quarter 2024
2 May 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
UPLOAD
Letter from SEC
29 Feb 24
S-8
Registration of securities for employees
27 Feb 24
Transcripts
KURA
Earnings call transcript
2024 Q1
2 May 24
KURA
Earnings call transcript
2023 Q3
2 Nov 23
KURA
Earnings call transcript
2023 Q2
3 Aug 23
KURA
Earnings call transcript
2023 Q2
3 Aug 23
KURA
Earnings call transcript
2023 Q1
10 May 23
KURA
Earnings call transcript
2022 Q4
23 Feb 23
KURA
Earnings call transcript
2022 Q3
3 Nov 22
KURA
Earnings call transcript
2022 Q2
3 Aug 22
KURA
Earnings call transcript
2022 Q1
5 May 22
KURA
Earnings call transcript
2021 Q4
25 Feb 22
Latest ownership filings
4
Mary T Szela
7 Jun 24
4
Diane L. Parks
7 Jun 24
4
CAROL SCHAFER
7 Jun 24
4
Thomas Malley
7 Jun 24
4
Faheem Hasnain
7 Jun 24
4
Helen Louise Collins
7 Jun 24
4
Teresa Brophy Bair
20 May 24
144
Notice of proposed sale of securities
20 May 24
SC 13G
Paradigm Biocapital Advisors LP
2 May 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 41.51 mm | 41.51 mm | 41.51 mm | 41.51 mm | 41.51 mm | 41.51 mm |
Cash burn (monthly) | (no burn) | (no burn) | 18.15 mm | 15.31 mm | 16.28 mm | 11.48 mm |
Cash used (since last report) | n/a | n/a | 70.17 mm | 59.18 mm | 62.95 mm | 44.40 mm |
Cash remaining | n/a | n/a | -28.67 mm | -17.68 mm | -21.44 mm | -2.89 mm |
Runway (months of cash) | n/a | n/a | -1.6 | -1.2 | -1.3 | -0.3 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 164 |
Opened positions | 76 |
Closed positions | 8 |
Increased positions | 34 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 1.69 tn |
Total shares | 88.84 mm |
Total puts | 120.10 k |
Total calls | 913.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Suvretta Capital Management | 7.07 mm | $150.80 bn |
BLK Blackrock | 6.90 mm | $147.16 bn |
EcoR1 Capital | 5.81 mm | $123.86 bn |
Deerfield Management | 5.41 mm | $115.43 bn |
Flynn James E | 5.31 mm | $0.00 |
BVF | 4.79 mm | $102.09 bn |
STT State Street | 4.20 mm | $89.59 bn |
Vanguard | 4.07 mm | $86.73 bn |
Avoro Capital Advisors | 3.85 mm | $82.12 bn |
Biotechnology Value Fund L P | 3.80 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jun 24 | Szela Mary T | Option to purchase common stock Common Stock | Grant | Acquire A | No | No | 21.79 | 26,000 | 566.54 k | 26,000 |
5 Jun 24 | Parks Diane L. | Option to purchase common stock Common Stock | Grant | Acquire A | No | No | 21.79 | 26,000 | 566.54 k | 26,000 |
5 Jun 24 | Schafer Carol | Option to purchase common stock Common Stock | Grant | Acquire A | No | No | 21.79 | 26,000 | 566.54 k | 26,000 |
5 Jun 24 | Malley Thomas | Option to purchase common stock Common Stock | Grant | Acquire A | No | No | 21.79 | 26,000 | 566.54 k | 26,000 |
5 Jun 24 | Hasnain Faheem | Option to purchase common stock Common Stock | Grant | Acquire A | No | No | 21.79 | 26,000 | 566.54 k | 26,000 |
News
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
18 Jun 24
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
16 May 24
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
14 May 24
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
6 May 24
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
3 May 24
Press releases
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Jul 24
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
18 Jun 24
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 Jun 24
Kura Oncology to Participate in Jefferies Global Healthcare Conference
29 May 24
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
14 May 24